206 related articles for article (PubMed ID: 22138753)
1. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
Luker KE; Mihalko LA; Schmidt BT; Lewin SA; Ray P; Shcherbo D; Chudakov DM; Luker GD
Nat Med; 2011 Dec; 18(1):172-7. PubMed ID: 22138753
[TBL] [Abstract][Full Text] [Related]
2. Split Gaussia luciferase for imaging ligand-receptor binding.
Luker KE; Luker GD
Methods Mol Biol; 2014; 1098():59-69. PubMed ID: 24166368
[TBL] [Abstract][Full Text] [Related]
3. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.
Luker K; Gupta M; Luker G
Biotechniques; 2009 Jul; 47(1):625-32. PubMed ID: 19594447
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
5. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
6. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
7. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
8. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
9. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
10. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
11. Dual-Color Luciferase Complementation for Chemokine Receptor Signaling.
Luker KE; Luker GD
Methods Enzymol; 2016; 570():119-29. PubMed ID: 26921944
[TBL] [Abstract][Full Text] [Related]
12. Effects of the chemokine CXCL12 and combined internalization of its receptors CXCR4 and CXCR7 in human MCF-7 breast cancer cells.
Hattermann K; Holzenburg E; Hans F; Lucius R; Held-Feindt J; Mentlein R
Cell Tissue Res; 2014 Jul; 357(1):253-66. PubMed ID: 24770893
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
14. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.
Ray P; Lewin SA; Mihalko LA; Lesher-Perez SC; Takayama S; Luker KE; Luker GD
Biochem J; 2012 Mar; 442(2):433-42. PubMed ID: 22142194
[TBL] [Abstract][Full Text] [Related]
15. Imaging chemokine receptor dimerization with firefly luciferase complementation.
Luker KE; Gupta M; Luker GD
FASEB J; 2009 Mar; 23(3):823-34. PubMed ID: 19001056
[TBL] [Abstract][Full Text] [Related]
16. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
[TBL] [Abstract][Full Text] [Related]
17. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
18. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
19. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
20. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
